GPP
PDLI

Great Point Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Great Point Partners’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-645,000
Closed -$2.16M – 43
2016
Q3 		$2.16M Buy
+645,000
New +$2.05M 0.55% 25

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Great Point Partners's PDLI Position: Q4 2016 in Review

Great Point Partners sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 645,000 shares — an estimated $2.16M sold.

Great Point Partners first reported a position in PDLI in Q3 2016 and held it in 1 quarter. The position peaked at $2.16M in Q3 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • Great Point Partners reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Great Point Partners sold 645,000 PDL BioPharma, Inc. shares in Q4 2016, an estimated $2.16M.
  • Great Point Partners first reported a position in PDL BioPharma, Inc. in Q3 2016 and held it in 1 quarter.
  • Great Point Partners's PDL BioPharma, Inc. position peaked at $2.16M in Q3 2016.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Great Point Partners's 13F filing for Q4 2016, filed 14 Feb 2017.